Bausch Health Companies Inc.
BHC | NYSE
$5.64
-$0.03 (-0.53%)
At close: Sep 21, 2026, 4:00 PM ET
$5.65
+$0.01 (+0.20%)
After-hours:
Sep 21, 2026, 5:56 PM ET
Company Profile
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.
Key Executives
| Name | Position |
|---|---|
| Thomas J. Appio | Chief Executive Officer & Director |
| Jean-Jacques Charhon | Executive Vice President & Chief Financial Officer |
| Mirza Dautbegovic | Executive Vice President & Chief Operating Officer |
| Aimee J. Lenar | President of US Pharma |
| Cees Heiman | Senior Vice President of Europe & Canada |
| Garen Sarafian | Vice President & Head of Investor Relations |
| Jiny Kim | Senior Vice President of Solta Medical |
| Kathleen Fitzpatrick | Executive Vice President and Chief HR & Communications Officer |
| Seana Carson | Executive Vice President & General Counsel |
| Steven Lee | Senior Vice President, Controller & Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 20, 2026 | 4 | Filing |
| Jul 30, 2026 | 10-Q | Quarterly Report |
| Jul 29, 2026 | 8-K | Current Report |
| Jul 20, 2026 | 4 | Filing |
| Jul 17, 2026 | 4 | Filing |
| Jul 15, 2026 | 4 | Filing |
| Jul 02, 2026 | 4 | Filing |
| Jul 02, 2026 | 4 | Filing |
| Jul 02, 2026 | 4 | Filing |
| Jul 01, 2026 | 8-K | Current Report |
Bausch Health Companies Inc.
| Country | Canada |
| IPO Date | Mar 28, 1994 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 20,300 |
| CEO | Thomas J. Appio |
Contact Details
2150 St. ElzEar Boulevard West Laval,
QC H7L 4A8 Canada
Stock Details
| Ticker Symbol | BHC |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000885590 |
| CUSIP Number | 071734107 |
| ISIN Number | CA0717341071 |
| SIC Code | 2834 |
Recent News
- 1 day ago / defenseworld.netBausch Health Cos Inc. (NYSE:BHC) Receives $8.00 Consensus Target Price from Brokerages
- 4 days ago / defenseworld.netEngineers Gate Manager LP Raises Stock Position in Bausch Health Cos Inc. $BHC
- 8 days ago / zacks.com4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike
- 14 days ago / prnewswire.comBausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets
- 29 days ago / businesswire.comBausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
- 1 month ago / zacks.comCan Bausch (BHC) Run Higher on Rising Earnings Estimates?
- 1 month ago / zacks.comBausch (BHC) Upgraded to Buy: Here's What You Should Know
- 1 month ago / seekingalpha.comBausch + Lomb: The Market Is Pricing The Balance Sheet, Not The Eye-Care Engine
- 1 month ago / seekingalpha.comBausch Health: Q2 Beat And Cheap, But Debt Overhang Remains Substantial
- 1 month ago / zacks.comWhy Bausch Health (BHC) is a Top Momentum Stock for the Long-Term
Add to Watchlist
Select watchlists to add or remove BHC